AbCellera

About

AbCellera is an antibody discovery and development engine, finding optimal clinical candidates for our partners.

Vancouver,British Columbia,Canada
https://www.abcellera.com/

Highlights

Details

Last Funding Type: Series Unknown
Last Funding Money Raised: $817.87K
Industries: Artificial Intelligence,Biotechnology,Machine Learning,Medical,Therapeutics
Founded date: Jan 1, 2012
Operating Status: Active
Stock Symbol: nasdaq:ABCL
Legal Name: AbCellera Biologics Inc.

AbCellera is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic – and patients – sooner.

With the integrated AbCellera platform, our experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set our partners up for enduring success. 

We have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

11

$853.21M

AbCellera has raised a total of $853.21M in funding over 2 rounds. Their latest funding was raised on Dec 10, 2020 from a IPO round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 10, 2020	IPO	$482M	—	—	—	Detail
May 27, 2020	Series B	$105M	8	DCVC OrbiMed	—	Detail
May 3, 2020	Grant	$175.60M	1	Government of Canada	—	Detail
Mar 23, 2020	Series A	$75M	5	DCVC Bio OrbiMed	—	Detail
Mar 14, 2019	Grant	$4.80M	1	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

2

0

AbCellera has made 2 investments. Their most recent investment was on Sep 30, 2020, when Invetx raised $10.25M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Sep 30, 2020 Invetx	Series A	$10.25M	Biopharma	—
Feb 24, 2020 Invetx	Series A	$15M	Biopharma	—

Investors

Number of Lead Investors

Number of Investors

6

12

AbCellera is funded by 12 investors. DCVC and OrbiMed are the most recent investors.

Investor Name	Lead Investor	Funding Round
DCVC	Yes	Series B
OrbiMed	Yes	Series B
Government of Canada	Yes	Grant
DCVC Bio	Yes	Series A
Eli Lilly	—	Series B
Founders Fund	—	Series B
Peter Thiel	—	Series B
Presight Capital	—	Series B
University of Minnesota	—	Series B
Viking Global Investors	—	Series B

Employee Profiles

Number of Employee Profiles

10

AbCellera has 10 current employee profiles, including Board member John Hamer

Board member

Executive

Executive

Executive

Employee

Acquisition

AbCellera has acquired 4 organizations. Their most recent acquisition was Lineage Biosciences on Aug 1, 2018. They acquired Lineage Biosciences for 0.

Date Company Name	Industry	Acquisition Type	Price
Aug 1, 2018 Lineage Biosciences	Biotechnology	acquisition	—	Detail
Aug 20, 2020 Dualogics - OrthoMab	Biotechnology	acquisition	—	Detail
Nov 18, 2020 Trianni	Biotechnology	acquisition	$ 90M	Detail
Sep 13, 2021 Tetragenetics	Biopharma	acquisition	—	Detail